Daré Bioscience begins phase 2 trial of HPV infection treatment

May 18, 2026 8:01 AM

Daré Bioscience Inc. (NASDAQ: DARE) announced it has initiated a Phase 2 clinical study of DARE-HPV, an investigational treatment for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found